Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Shoots For Next Growth Phase In India With Bigger Push Into Vaccines, Pharma And Consumer Health

This article was originally published in The Pink Sheet Daily

Executive Summary

For the first time, the global board of directors of the British pharma and consumer healthcare giant met in India, and a series of moves to power further growth could be on the way.

You may also be interested in...

GSK CEO Calls For Change In Business Model As World Power Moves To Emerging Economies

MUMBAI - Fifty years from now, the period between 2005 and 2020 may be seen as critical years of change when the world witnessed a fundamental shift in economic power from a model dominated for the last 250 years to an evolutionary one led by emerging markets rather than Western economies

In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket

Need For A Vaccines Unit In India Pushes GSK Closer To Align With India's Biological E; Is A Buyout Imminent ?

MUMBAI - GlaxoSmithKline Plc.'s vaccines arm, the Belgium-headquartered GSK Biologicals S.A. is believed to be on course to acquire Hyderabad, India-based vaccines manufacturer Biological E. Ltd., a report in The Economic Times said last week. If the deal comes to fruition, GSK would fulfil its long desire to buy an Indian asset that could be leveraged for its expanding network in the high potential emerging markets

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts